關鍵數據
0.600今開
0.638最高
6.30K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.02%換手率
0.600昨收
0.583最低
3.75K成交額
虧損本益比靜
-0.54市淨率
0.00%股息率 TTM
-19.77%ROA
5.33052週最高
0.03量比
-38.07M淨利潤
27.29M總股本
-0.6509每股盈餘TTM
0.56Beta
-2440.41%ROE
0.40052週最低
9.17%振幅
58.79%毛利率
16.54M總市值
19.44回報/風險
7.09%風險率

即將為您帶來更多新聞,敬請期待。 。 。
MDxHealth SA評分
-0.15與上次評分對比預測7.67
財務診斷7.51
技術分析4.51
公司估值9.30
機構認同度3.00
風險評估1.60
分析師評級
買入評級
1.400目標均價
+133.37%漲幅空間
MDxHealth SA 最新財報電話會記錄
MDxHealth (MDXH) 2026年第二季法說會:營收回升,維持財測指引
MDxHealth 2026 年第二季營收成長 16% 至 2,720 萬美元。該公司維持 1.1 億至 1.15 億美元的財測指引,並以在 2026 年底前實現調整後 EBITDA 轉正為目標。
財務指標
貨幣: USD

由於公司未披露,未能獲取相關數據
貨幣: USD

由於公司未披露,未能獲取相關數據
MDxHealth SA 簡介
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
行業生物技術與醫療研究
公司代碼MDXH
員工數量312
國家Belgium
持股情況
| 持股股東 | 佔比 |
|---|
| Bleichroeder LP | 14.36% |
|---|
| AWM Investment Company, Inc. | 10.17% |
|---|
| MVM Partners LLP | 9.15% |
|---|
| Lytton (Laurence W) | 6.13% |
|---|
| 股東類型 | 佔比 |
|---|
| Investment Advisor | 20.86% |
|---|
| Investment Advisor/Hedge Fund | 16.23% |
|---|
| Venture Capital | 9.23% |
|---|
| Individual Investor | 6.38% |
|---|
常見問題
MDxHealth SA(MDXH)的當前股價是多少?
MDxHealth SA(MDXH)的當前股價是 0.60。
MDxHealth SA股票的52週最高點是多少?
MDxHealth SA股票的52週最高點是5.33。
MDxHealth SA股票的52週最低點是多少?
MDxHealth SA股票的52週最低點是0.40。
現在MDxHealth SA(MDXH)的股票是買入、持有還是賣出?
根據分析師評級,MDxHealth SA(MDXH)的總體評級為買入,目標價格為1.40。
MDxHealth SA(MDXH)股票的每股收益(EPS TTM)是多少
MDxHealth SA(MDXH)股票的每股收益(EPS TTM)是-0.65。